NASDAQ
02.10.26 | 22:00
2,020 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Foghorn Therapeutics-Aktie stürzt nach gescheiterter Lilly-Kooperation und Analysten-Downgrades ab | 13 | Investing.com Deutsch | ||
| Fr | Wedbush cuts Foghorn Therapeutics stock rating on drug setback | 2 | Investing.com | ||
| Fr | Guggenheim cuts Foghorn Therapeutics price target on drug setback | 1 | Investing.com | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt | 2 | Investing.com | ||
| Do | Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt | 4 | Investing.com | ||
| Do | TD Cowen stuft Foghorn Therapeutics nach Studienabbruch auf "Halten" herab | 4 | Investing.com Deutsch | ||
| Do | Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation | 3 | Investing.com | ||
| Do | Citizens stuft Foghorn Therapeutics nach Einstellung von Medikamentenentwicklung herab | 3 | Investing.com Deutsch | ||
| Do | Stifel senkt Kursziel für Foghorn Therapeutics nach Pipeline-Neuausrichtung | 1 | Investing.com Deutsch | ||
| Do | Stifel cuts Foghorn Therapeutics stock price target on pipeline shift | 1 | Investing.com | ||
| Do | Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal | 2 | Benzinga.com | ||
| Do | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | 367 | GlobeNewswire (Europe) | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| Do | Foghorn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | Citizens bestätigt Einstufung für Foghorn Therapeutics vor wichtigen Studiendaten | 17 | Investing.com Deutsch | ||
| 17.09. | Citizens reiterates Foghorn Therapeutics stock rating on trial data | 2 | Investing.com | ||
| 17.08. | Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 | 2 | Investing.com | ||
| 06.08. | Foghorn Therapeutics GAAP EPS of -$0.10 beats by $0.14, revenue of $16.1M beats by $8.17M | 2 | Seeking Alpha | ||
| 06.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? | 2 | Zacks |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,230 | -0,65 % | Novavax Inc mit PAUKENSCHLAG: Droht die Aktie jetzt der nächste Absturz? - Jetzt unbedingt lesen! | ||
| INOVIO PHARMACEUTICALS | 1,067 | +3,09 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,533 | -0,45 % | InflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development | Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,900 | 0,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 2,210 | -5,15 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,411 | +4,05 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| IBIO | 0,963 | -3,60 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,095 | +3,06 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 9,110 | -0,33 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,690 | -0,74 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 4,004 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,533 | +4,77 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,820 | -1,37 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 7,054 | -0,06 % | IMMUNIC, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| EMERGENT BIOSOLUTIONS | 5,555 | -1,33 % | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG... ► Artikel lesen |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.